1. Home
  2. XTNT vs TCRX Comparison

XTNT vs TCRX Comparison

Compare XTNT & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xtant Medical Holdings Inc.

XTNT

Xtant Medical Holdings Inc.

HOLD

Current Price

$0.44

Market Cap

61.7M

Sector

Health Care

ML Signal

HOLD

Logo TScan Therapeutics Inc.

TCRX

TScan Therapeutics Inc.

HOLD

Current Price

$0.79

Market Cap

49.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XTNT
TCRX
Founded
N/A
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
61.7M
49.4M
IPO Year
2009
2021

Fundamental Metrics

Financial Performance
Metric
XTNT
TCRX
Price
$0.44
$0.79
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$1.00
$7.00
AVG Volume (30 Days)
74.0K
644.9K
Earning Date
05-08-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
125.00
12.28
EPS
N/A
N/A
Revenue
$53,337,000.00
$10,325,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$9.30
$19.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
266.65
52 Week Low
$0.39
$0.72
52 Week High
$0.95
$2.57

Technical Indicators

Market Signals
Indicator
XTNT
TCRX
Relative Strength Index (RSI) 53.48 39.31
Support Level $0.44 N/A
Resistance Level $0.49 $1.16
Average True Range (ATR) 0.03 0.06
MACD 0.00 -0.01
Stochastic Oscillator 54.58 18.58

Price Performance

Historical Comparison
XTNT
TCRX

About XTNT Xtant Medical Holdings Inc.

Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.

About TCRX TScan Therapeutics Inc.

TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Share on Social Networks: